Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: Successful treatment by arsenic trioxide in combination with local radiotherapy

International Journal of Hematology

Volumn 83, Issue 4, 2006, Pages 337-340

  Kai, Tatsuyuki ^a,b   Kimura, Hideo ^a   Shiga, Yutaka ^a   Ogawa, Kazuei ^a   Sato, Hisashi ^a   Maruyama, Yukio ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b Fukushima Medical University   (Japan)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic trioxide; Extramedullary relapse; Stem cell transplantation

Indexed keywords

ACLARUBICIN; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BUSULFAN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ENOCITABINE; ETOPOSIDE; MITOXANTRONE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CASE REPORT; CELL SUSPENSION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MORPHOLOGY; PROMYELOCYTIC LEUKEMIA; RARE DISEASE; RECURRENT CANCER; TREATMENT OUTCOME; TUMOR CELL;

ANTINEOPLASTIC AGENTS; ARSENICALS; CHROMOSOMES, HUMAN, PAIR 15; CHROMOSOMES, HUMAN, PAIR 17; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MIDDLE AGED; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; OXIDES; RECURRENCE; REMISSION INDUCTION; SARCOMA, GRANULOCYTIC; STEM CELL TRANSPLANTATION; TRANSLOCATION, GENETIC; TRANSPLANTATION, HOMOLOGOUS; TRETINOIN;

EID: 33744469061     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05167     Document Type: Article

References (21)

1. Grignani F, Fagioli M, Alcalay M, et al. Acute promyelocytic leukemia: from genetics to treatment. Blood. 1994;83:10-25.
2. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood. 1999;94:12-22.
3. Bekassy AN, Hermans J, Gorin NC, Gratwohl A. Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1996;17:801-808.
4. Forrest DL, Dalal BI, Naiman SC, et al. Testicular relapse of acute promyelocytic leukemia after allogeneic BMT. Bone Marrow Transplant. 1997;20:689-690.
5. Milone G, Inghilterra G, Li Gioi F, Peluso D, Giustolisi R. Testicular and cutaneous relapse after hematopoietic transplantation in a patient affected with APL. Bone Marrow Transplant. 1999;23:751.
6. Ustun C, Arat M, Celebi H, et al. Extramedullary relapse following allogeneic stem cell transplantation in acute promyelocytic leukemia: the role of ATRA. Haematologica. 2001;86:E31.
7. Classen CF, Debatin KM, Friedrich W, Schulz AS. Long-term remission of APL with a second allogeneic BMT after CNS relapse following HLA-identical allogeneic BMT. Bone Marrow Transplant. 2003;32:843-846.
8. Ammatuna E, Borza PA, Iori AP, et al. Multiple relapses and extramedullary localization with scalp and breast involvement in a case of acute promyelocytic leukaemia. Leukemia. 2005;19: 479-480.
9. Evans GD, Grimwade DJ. Extramedullary disease in acute promyelocytic leukemia. Leuk Lymphoma. 1999;33:219-229.
10. Ko BS, Tang JL, Chen YC, et al. Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia; the occurrence of retinoic acid syndrome is a risk factor. Leukemia. 1999;13:1406-1408.
11. Di Noto R, Lo Pardo C, Schiavone EM, et al. All-trans retinoic acid (ATRA) and the regulation of adhesion molecules in acute myeloid leukemia. Leuk Lymphoma. 1996;21:201-209.
12. Ito S, Ishida Y, Oyake T, et al. Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia. Leuk Lymphoma. 2004;45:1783-1789.
13. Specchia G, Lo Coco F, Vignetti M, et al. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J Clin Oncol. 2001;19: 4023-4028.
14. Sanz MA, Larrea L, Sanz G, et al. Cutaneous promyelocytic sarcoma at sites of vascular access and marrow aspiration: a characteristic localization of chloromas in acute promyelocytic leukemia? Haematologica. 2000;85:758-762.
15. Lee KH, Lee JH, Choi SJ, et al. Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course. Bone Marrow Transplant. 2003;32:835-842.
16. Goldberg SL, Mangan KF, Klumpp TR, Cropper TM, Schnall SF, Macdonald JS. Lack of graft-versus-leukemia effect in an immunologically privileged sanctuary site. Bone Marrow Transplant. 1994; 14:180-181.
17. Au WY, Lie AK, Liang R, Kwong YL. Isolated extramedullary relapse of acute lymphoblastic leukaemia after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;24: 1137-1140.
18. 3) in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89: 3354-3360.
19. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852-3860.
20. Tsimberidou AM, Estey E, Whitman GJ, et al. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res. 2004;28:991-994.
21. Griffin RJ, Williams BW, Park HJ, Song CW. Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy. Int J Radiat Oncol Biol Phys. 2005;61:1516-1522.